Blood test to guide extra stomach or esophagus cancer treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial checks whether a blood test after surgery (ctDNA) can help decide if you should receive additional “adjuvant” treatment for stomach, gastroesophageal junction, or lower esophagus cancer that has HER2-positive tumors. It may help reduce the chance of cancer coming back by tailoring therapy to your risk based on the ctDNA result.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a stomach, gastroesophageal junction, or lower esophagus adenocarcinoma with HER2-positive tumor results
- After surgery, your ctDNA blood test (Signatera) must be positive
- You had chemotherapy before surgery for at least 6 weeks, then surgery removed the tumor completely with clear margins (R0)
- A scan after surgery must show no spread to other organs (no metastases)
- Your heart and organ tests must meet safety thresholds (including LVEF at least 50%) and you must be well enough for treatment (ECOG 0–1)
- You must not have had prior HER2-targeted therapy such as trastuzumab, and you must have recovered well from surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using a blood test for cancer DNA (ctDNA) can help decide if more chemotherapy is needed after surgery and chemo for advanced stomach cancer. It may help tailor treatment to your individual risk of cancer returning.
This study tests whether a simple blood test (called ctDNA) can help decide if you need additional chemotherapy after surgery for stomach or esophageal cancer. The goal is to avoid unnecessary treatment for patients who are already cancer-free while ensuring those who need it get the right therapy.
This trial tests whether using a blood test for tumor DNA (ctDNA) can help decide who needs more chemotherapy after surgery for advanced stomach cancer. The goal is to personalize treatment and avoid unnecessary side effects.
This trial tests adding pembrolizumab to standard trastuzumab and chemotherapy for people with HER2-positive stomach or esophageal cancer that can be fully removed with surgery. The goal is to see if this combination improves outcomes before and after surgery.
This trial tests whether combining different drugs before and after surgery can help people with locally advanced stomach cancer that can't be removed right away. The goal is to see which combination works best to shrink the tumor and improve outcomes.
This trial tests two targeted drugs, trastuzumab deruxtecan and afatinib, together for advanced stomach or gastroesophageal junction cancer that has low levels of the HER2 protein. The goal is to see if the combination shrinks tumors or slows cancer growth.
Hear when a new Gastrooesophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.